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3Abstract
Background
Overt albuminuria (urinary albumin-creatinine ratio (ACR) >300mg/g) is an established risk
factor for progression of nephropathy and total mortality. However, whether, a reduction in
ACR translates into a reduction in mortality and/or cardiovascular events among insulin-
treated patients with Type 2 diabetes (T2D) in routine practice is currently not known.
Methods
We obtained data on a large cohort of insulin users with T2D and nephropathy (baseline ACR
≥ 300mg/g) from UK general practices between 2007 and 2014. Their corresponding ACR 
values after one year of follow up were thereafter categorised into: (1) <300mg/g (i.e.
albuminuria regression) or (2) >300mg/g (i.e. non-regression of albuminuria), and the cohort
was followed up for 5 years for all-cause mortality and cardiovascular events. Cox
proportional hazard models were fitted to estimate the risk of all-cause death.
Results
A total of 11,074 patients with insulin-treated T2D met the inclusion criteria. Their mean age
was 62.3(13.6) years; mean HbA1c: 8.7(1.8) %; and 53% were male. 682 deaths occurred
after a follow-up period of 43,393 person-years with a mortality rate of 16 per 1000 person-
years. 5-year survival was markedly reduced in the group whose proteinuria persisted or
progressed (91 vs 95%; log-rank p-value <0.001). Compared to patients whose ACR levels
remained above 300mg/g, all-cause mortality and cardiovascular events were 31% and 27%
lower in those whose albuminuria regressed to <300mg/g (aHR: 0.69; 95%CI: 0.52 to 0.91;
p=0.008 and aHR: 0. 73; 95%CI: 0.54 to 0.98; p=0.041) respectively.
Conclusion
In patients with insulin-treated T2D and nephropathy in routine practice, a regression in
albuminuria (e.g. via better BP or glycaemic control) is associated with a significant
reduction in all-cause mortality. Thus, albuminuria is not simply a risk marker of renal and
cardiovascular disease, but also an independent target for therapy. Albuminuria reduction
should be viewed as a goal for renal and cardiovascular protection.
4Research in context:
What is already known about this subject?
 Albuminuria is a strong predictor of adverse renal and cardiovascular outcomes in
patients with Type 2 Diabetes (T2D), hypertension and in the general population.
 Several therapeutic strategies are available to reduce ACR, namely via interruption of
the Renin-Angiotensin system (RAS) with either angiotensin-converting enzyme
(ACE) inhibitors or Angiotensin II receptor blocker; strategies to achieve tight
glucose control; and the use of Sodium Glucose co-transporter (SGLT)-2 inhibitor.
 Previous sub-analysis of studies have shown that the reduction in albuminuria
achieved in the first months of RAS blockade predicts long-term renal and
cardiovascular risk reduction
What is the key question?
 Among patients with Insulin treated Type 2 diabetes with overt proteinuria
(ACR>300g/g), undergoing routine treatment in primary care, does regression of
proteinuria confer an associated reduction in cardiovascular events and total mortality
compared with patients whose proteinuria did not regress?
What are the new findings?
 Among this cohort of patients with Insulin treated Type 2 diabetes, increased
albuminuria is an independent marker for subsequent cardiovascular events and total
mortality in real world setting.
 Regression of albuminuria as a result of multifactorial intervention in routine clinical
care was associated with a further significant reduction in cardiovascular events and
total mortality events compared with patients whose albuminuria did no regress.
 The beneficial impact of albuminuria regression appears to be stronger for total
mortality than for cardiovascular endpoints, regression of albuminuria is not
associated with a significant reduction in non-fatal myocardial infarction but, was
associated with a significant reduction in stroke event, compared with the cohort
whose albuminuria level either increased or did not regress.
How might this impact on clinical practice in the foreseeable future?
 Thus, levels of albuminuria should be considered not only as an important risk
marker, but also an important therapeutic target for cardiovascular and mortality
prevention in patients with T2D, and should be a key consideration when determining
drug choice irrespective of blood pressure and glucose levels.
5Introduction
Albuminuria is a strong predictor of adverse renal and cardiovascular outcomes in patients
with Type 2 Diabetes (T2D), hypertension and in the general population. [1-4] Albuminuria
is typically assessed by measuring urinary albumin to creatinine ratio (ACR). ACR levels
between 30mg/g to 300mg/g represent moderately increased levels of albuminuria, known as
microalbuminuria, while levels of more than 300mg/g are associated with overt proteinuria.
Several therapeutic strategies are available to reduce ACR, namely via interruption of the
Renin-Angiotensin system (RAS) with either angiotensin-converting enzyme (ACE)
inhibitors or Angiotensin II receptor blocker [5,6]; strict BP control; strategies to achieve
tight glucose control [7]; and more recently, the Sodium Glucose co-transporter (SGLT)-2
inhibitor [8,9]. While these strategies are also associated with improvement in renal and
cardiovascular outcomes, the precise impact of ACR reduction, independent of conventional
cardiovascular risk parameters, in mediating the beneficial effect of cardio-renal outcome
remains unclear.
For many patients with T2D, insulin treatment will be required to control hyperglycaemia and
to reduce the risk of long-term vascular complications in patients with T2D. [10-12].
However, insulin therapy is known to induce ~4-9 kg weight gain in the first year of
treatment. [13] This is relevant within the context of diabetic nephropathy since obesity is
also a significant risk factor for the appearance of proteinuria and ESRD. [14] Furthermore,
recent evidence from randomized controlled trial, epidemiological and observational studies
have implicated insulin therapy in patients with T2D with increased CV risk and mortality of
[15-18], possibly due to weight gain, recurrent hypoglycaemia, potential adverse effects of
iatrogenic hyperinsulinemia as well as a surrogate marker of increased diabetes duration
6[19.20]. Thus, a cohort of insulin-treated patients with T2D, represents a complex
heterogeneous challenging group of patients, many of whom have significant comorbidities
and high CV disease risk.
Although previous studies have shown that the reduction in albuminuria achieved in the first
months of RAS blockade predicts long-term renal and cardiovascular risk reduction [21, 22] -
implying a causal association between albuminuria with cardio-renal risks [23], no previous
study has been performed to investigate the independent effects of reduction in albuminuria
on cardiovascular events and total mortality among insulin-treated patients with T2D in real-
world primary care, given that insulin initiators usually have poor glycaemic control, longer
disease duration or may be more advanced in age, and a reduction in ACR amongst them
could be associated with marked reduction in these events.
Methods
Study Design
Using a large UK Primary Care database – The Health Improvement Network (THIN)
Database – we conducted a historic cohort study among patients with T2D currently on
insulin. THIN is a large UK electronic Primary Care database with clinical details of over
12.4 million patients, of which about 3.61 million are active. Data are imputed with the
longitudinal records from about 587 General Practices which are obtained and updated
regularly.
The routine clinical information of these patients are constantly and systematically entered
into this database by trained doctors and specialist nurses. Data of specialist or Primary Care
consultations, diagnoses, laboratory results, prescriptions, referrals, hospital admissions,
immunisations, to important clinical measures such as body weight, height and body mass
index (BMI) as well as information on the patients’ demography (e.g. age, and gender)
7lifestyle characteristics (e.g. alcohol use and smoking), socio-economic status (measured by
the Townsend deprivation scores) are also included.
THIN database has been validated by various studies and shown to be demographically
representative of the UK population in terms of indices of diseases and patients’ demography
[24]. Our research group has extensively used the THIN database in evaluating diabetes-
related outcomes in routine clinical practice [25,26].
Study Participants
We obtained routine clinical data on 11,074 patients with a diagnosis of T2D who met our
inclusion criteria. These were adults (aged 18 years and above) who were on insulin therapy
between December 2006 and May 2014, irrespective of the use of other glucose-lowering
therapies (GLTs). These patients must have recorded values of ACR at baseline and one year
after insulin initiation. Only those with those with nephropathy (ACR levels above 300mg/g)
were included. Urinary ACR in the dataset was measured from a single voided urine sample
by a central laboratory, with the lowest detectable and reportable level of 1.0mg/g.
Excluded from the study were those with missing baseline data of ACR and those with
medical codes for type 1 or gestational diabetes, or other forms of diabetes, alongside those
with no continuous regular prescriptions for insulin in their records for more than 6 months.
Follow-up and Endpoints
The selected study participants with nephropathy at insulin initiation (baseline date) were
followed up from this date for one year. Post-one year ACR levels were estimated and
patients were grouped into two: those with ACR levels now <300mg/g vs those with ACR ≥ 
300mg/g. Patients were then followed up from this point until occurrence of the primary or
secondary endpoint, or loss to follow-up, or discontinuation of insulin therapy, or at the end
of the 5-year follow-up period.
The primary endpoints were all-cause mortality and cardiovascular events (a composite of
non-fatal myocardial infarction and stroke).
8The secondary endpoint was a 3-composite of Major Adverse Cardiovascular Events
(MACE) which includes all-cause mortality or non-fatal myocardial infarction or stroke; and
the component parts of non-fatal myocardial infarction and stroke.
All these outcomes were identified using their appropriate Read Codes in the database.
Baseline and endpoint characteristics
To be able to adjust for the effect of possible a priori confounders on the study endpoints,
data were also obtained on important baseline clinical covariates Among these were
demographic variables as age, gender, socioeconomic status, alcohol and smoking status;
important clinical measures such as body weight, height, SBP and DBP; biochemical
parameters, e.g. baseline HbA1c, lipid-profile, use of other medications including other
glucose-lowering therapies (GLTs); as well as comorbidity status, duration of diabetes
treatment, and duration of insulin use. We computed the change in mean arterial pressure
(MAP) and HbA1c after one year of insulin initiation; and alongside baseline covariates with
significant differences between the two groups, these were adjusted for in the final Cox
model.
Statistical Analysis
Multiple imputations using the chained equation (MICE) model were used to input missing
data for some important baseline clinical covariates as weight, HbA1c, eGFR, weight, SBP
and DBP which were found to be completely missing at random (MAR).
Baseline data were summarised for the two groups using mean with standard deviations for
continuous variables; and absolute numbers with proportions (%) for categorical variables.
The differences in baseline characteristics between the two groups were estimated using
Pearson’s chi-squared test for categorical, and Student t-test for continuous variables.
Kaplan-Meier survival curves were estimated separately for both treatment groups. From
these survival functions, we calculated the absolute reduction in the probability of an event
occurring within the 5-year follow-up period.
Using the Cox regression model, the marginal Hazard Ratios (HRs) were estimated in order
to quantify the adjusted hazard (aHR) of an event occurring in the “ACR below 300mg/g”
9group compared with the “ACR 300mg/g and above” group. We tested for violations of the
proportional hazard assumption of the Cox regression model, by adding an interaction term of
the predictor; and by log-minus-log survival curves; and finally confirmed the proportional
hazards assumptions were through Schoenfeld residuals test.
Point estimates were computed with 95% confidence intervals (CI) at the conventional
statistical significance level of 0.05. Stata Software version 15 was used for all the analyses.
Ethical Approval:
This was obtained from the South-East Research Ethics Committee, UK
Results
Patient Characteristics.
A total of 11,074 new insulin initiators met our inclusion criteria. Of this, 1552 (14%) had
reduction in albuminuria, as against 9522 (86%) who had persistent or progressive
albuminuria after one year of intensive glucose control with insulin.
Their overall mean age was 62.3±14 years, mean baseline HbA1c and eGFR were 8.7±1.8%
and 59.9±21.2mls/min/1.73m2 respectively. Table 1 is a summary of the baseline
characteristics of the study participants, stratified by the two treatment groups.
From Table 1, it can be seen that at baseline, those with their post-one year ACR less than
300mg/g were younger (p < 0.001); less obese and overweight (p = 0.002); had less
comorbidities (p < 0.05); shorter duration of diabetes before insulin initiation (p = 0.004);
higher eGFR (p < 0.001); and lower systolic and diastolic BP (p < 0.05). Conversely, the use
of other GLTs, baseline HbA1c and lipid profile were similar in both groups (all p ≥ 0.05). 
Primary Endpoint
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i. All-Cause Mortality: Survival analyses at 5 years were 91% vs 95% for patients with
ACR above 300mg/g (group 1) vs those with ACR below 300mg/g (group 2); log-rank test p-
value <0.001 (Figure 1). Overall, there were 682 deaths with a crude incidence rate of 15.7
per 1000 person-years (95%CI: 14.6 to 17.0) within a total follow-up period of 43,393
person-time. There were 621 vs 61 deaths in group 1 vs 2.with an unadjusted mortality rates
of 16.7 vs 9.7 per 1000 person-years (Table 2).
In the unadjusted model, the risk of all-cause mortality was 43% less (aHR: 0.57, 95%CI:
0.44 to 0.75, p <0.001) in group 2 compared to group 1. Following adjustment for change in
HbA1c and Mean arterial pressure (MAP) and other significantly different baseline
covariates in Table 1 , this reduced to 31% (aHR: 0.69, 95%CI: 0.52 to 0.91, p=0.008) (Table
2)
ii. Cardiovascular (CV) Events: After a total follow-up period of 38,274 person-time, the 5-
year survival probabilities for CV events were 94% vs 96% in group 1 vs group 2 (log-rank
test p-value = 0.007); with an overall event rate of 12.6 per 1000 person-years (95%CI: 11.7
to 13.9) - 13.4 vs 5.6 per 1000person-years in group 1 vs 2 respectively (Table 2). The risk of
CV events was 27% less in group 1 (aHR: 0.73, 95%CI 0.54 to 0.98, p = 0.041) compared to
group 2, even after adjustment.
Secondary Endpoint
i. Composite MACE: The probability of survival for composite MACE fell from 98% in
both groups at year 1 to 84% vs 90% in group 1 and 2 respectively at 5 years (log-rank p-
value <0.001) Figure 3A. Overall, there were 1,173 composite MACE (1,062 in group 1 vs
111 in group 2) with a crude event rate of 30.7 per 1000 person-years (95%CI: 30.0 to 32.5).
See Table 3. The risk of MACE in the adjusted Cox model was 27% less in group 2
compared to group 1 (aHR: 0.737, 95%CI: 0.59 to 0.89, p = 0.002).
ii. Non-fatal Myocardial Infarction (MI) and Non-fatal Stroke: For non-fatal MI, there
were no differences in survival between both groups (log-rank test p-value = 0.086), unlike in
non-fatal stroke in which the survival probabilities fell from 99% at the first year to 94% vs
96% at 5 year (log-rank test p-value =0.03). These are shown in the Kaplan-Meier curves in
11
Figures 3B and C. In both groups, there was a total of 69 and 419 events of non-fatal MI and
stroke respectively (Event rates = 1.6 vs 10.6 per 1000 person-years). The events between the
two treatment groups are summarised in Table 3.
There was no statistically significant difference in the risk of non-fatal MI between the
treatment groups (aHR = 0.66, 95%CI: 0.26 to 1.70, p = 0.387) while for stroke, patients
whose proteinuria regressed to <300mg/g (group 2) had a 30% reduction (aHR = 0.72;
95%CI: 0.52 to 0.97; p = 0.032) in risk compared to those with persistent or progressive
proteinuria (group 2).
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Discussion
The present study showed that albuminuria is an independent marker for subsequent
cardiovascular events and total mortality in insulin-treated patients with T2D. Regression of
albuminuria as a result of multifactorial intervention in routine clinical care was associated
with a further significant reduction in cardiovascular events and total mortality events. This
association appears to be marginally stronger for total mortality than for cardiovascular
endpoints. In addition, we found that regression of albuminuria was associated with reduction
in non-fatal myocardial infarction (though not statistically significant) but, interestingly, was
associated with a significant reduction in stroke event, compared with the cohort whose
albuminuria level either increased or did not regress. Thus, levels of albuminuria should be
considered not only as an important risk marker, but also an important therapeutic target for
cardiovascular and mortality prevention in patients with T2D, and should be a key
consideration when determining drug choice irrespective of blood pressure and glucose
levels.
Albuminuria has long been recognised to be a risk marker for the severity of kidney disease.
Although early opinion suggests that albuminuria is simply a surrogate marker of renal
injury, evidence in the last 12 years however, have shown the cause-effect relationship
between albuminuria and progressive kidney damage [21-23]. Our present study, obtained in
a large retrospective cohort of patients with insulin-treated T2D undergoing routine care in
UK general practices, shows that this phenomenon may also apply to cardiovascular event
and total mortality. This is akin to the impact of blood pressure and serum cholesterol,
where therapeutic strategies have been designed and with the aim to lower blood pressure and
serum cholesterol respectively. Indeed, there are recognised therapeutic strategies that can
13
reduce the degree of albuminuria – namely antihypertensive agents such as ACE inhibitor
and Angiotensin-2 receptor blocker [5,6], tight glucose control [7], SGLT2 inhibitors [8,9 ],
and low protein diet [27]. Since RAS blockade and SGLT2 inhibitor also lower blood
pressure, it remained speculative whether the changes in albuminuria per se affect the
cardiovascular/mortality endpoints independently of blood pressure. However, individual
variations to RAS blockade is well described – i.e. patients can have a systolic blood pressure
reduction without a simultaneous reduction in albuminuria or vice versa [28]. This
discordance in response to RAS blockade has been reported in clinical trial [29] as well as in
population treated in routine clinical practice [30], and that the beneficial impact of
albuminuria reduction was reported to be independent of blood pressure reduction. A
particularly important finding from this present study was the fact that the cardiovascular and
total mortality reduction was not observed in the cohort whose albuminuria did not regress,
following adjustment for conventional cardiovascular factors. The current study for the first
time shows on a large scale, in a real-world practice that the degree of albuminuria reduction
is directly related to the subsequent cardiovascular and mortality protection in a high risk
group of patients with T2D.
In the absence of a prospectively-designed clinical study, with appropriate treatment arms
and robust endpoints, the mechanism linking albuminuria and excess mortality remains
speculative. The Steno hypothesis suggested that urinary protein excretion reflects
generalised vascular endothelial dysfunction [31] – e.g. increased circulating von Willebrand
Factor (vWF) antigen released [32] and nitric oxide inhibition [33] in response to endothelial
cell damage. In addition to vWF, soluble vascular cell adhesion molecule, fibrinogen, high
platelet adhesiveness, erythrocytes aggregation and tissue plasminogen activator have been
found to correlate with urinary albumin excretion [34], especially in patients with diabetes,
14
indicating increased thrombosis risk. Proteinuria is also linked with insulin resistance, a
recognised marker and mediator of atherogenesis [35]. More recently, a key mechanism that
contributes to the link between albuminuria and adverse cardiovascular outcome relates to the
loss of the glycocalyx--a polysaccharide gel that lines the luminal endothelial surface and that
normally acts as a barrier against albumin filtration [36]. Degradation of the glycocalyx in
response to endothelial activation can lead to albuminuria and subsequent vascular
inflammation, thus providing a pathophysiological framework for the clinical association of
albuminuria with renal and cardiovascular disease progression.
The main strength of our study derives from the inclusion of a large cohort of patients with
T2D receiving insulin therapy in a real-world population which is largely representative of
the UK population. This implies that our findings will be generalizable to various population
that share similar demographics. The large cohort of patients studied here provides adequate
statistical power which also enabled the component endpoints to be studied. It also contains
information on other time-varying covariates to adjust for possible confounders. We adjusted
for a large set of factors that could have differed at the baseline. Nevertheless, some residual
confounding in our study could persists. For example, our classification of albuminuria was
largely based on a single measurement, in contrast to current recommendation, in which at
least two measurements are required. In addition, as is the case in all studies of CV or ESRD
risk associated with eGFR and albuminuria, the effect of competing hazards may bias
estimates of risk. This is because elevated ACR and low eGFR are also risk factors for non-
renal diseases, associated differential mortality in high-risk individuals may confound hazard
ratio estimates for CV events. Lastly, changes after baseline in medications were not
evaluated in this analysis and therefore cannot account for any differences that might
influence the association between ACR and outcomes.
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In summary, the findings of this study extend the cause-effect relationship between
albuminuria and cardiovascular risks and that suppressing albuminuria should be an
important target of therapy to achieve optimal cardiovascular protection in high risk
individuals with T2D. While further prospective interventional studies are required to clarify
the cause effect relationship, we would suggest that cardiovascular risk reduction guidelines
on patients with T2D should not only view albuminuria as an important risk factor/marker,
but should also define albuminuria regression as a target for therapy, similar to lipids, blood
pressure and glucose targets.
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Legend
Table 1 - Baseline Characteristics of Study Participants
Table 2: Comparison of number of events, Event rate and Hazard Ratio of the Primary
Outcomes between the treatment groups.
Table 3: Comparison of number of events, Event rate and Hazard Ratio of the Secondary
Outcomes between the treatment groups.
Figure 1 - Kaplan-Meier survival analysis plot for All-cause Mortality between the two
treatment groups (log-rank test p value < 0.001).
Figure 2 - Kaplan-Meier survival analysis plot for Cardiovascular Events between the
treatment groups (log-rank test p value = 0.007).
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Figure 3 - Kaplan-Meier survival analysis plot for (A) 3-point Composite Endpoint (log-rank
test p value = 0.006). (B) Non-fatal Acute Myocardial Infarction (log-rank test p-value
=0.086). (C) Non-Fatal Stroke (log-rank test p value = 0.03).
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Table 1: Baseline Characteristics
Baseline Variables
Post One-year ACR Categories
≥300mg/g 
(n = 9,522)
<300mg
(n = 1,552)
Total
(n = 11,074) p-value
Demographics
Age (yrs), Mean (SD) 62.8 (13.5) 59.8 (13.5) 62.3 (13.6) <0.001
Gender, No. (%)
Male 5070 (53) 829 (53) 5899 (53) 0.901
Townsend deprivation, No. (%)
Least deprived 1809 (20) 318 (21) 2127 (19)
2nd quintile 1835 (20) 301 (20) 2136 (19)
3rd quintile 1948 (21) 310 (21) 2258 (20) 0.734
4th quintile 1980 (22) 313 (21) 2293 (21)
Most deprived 1504 (17) 241 (16) 1745 (16)
Clinical Parameters, Mean (SD)
HbA1c (%) 8.8 (1.8) 8.7 (1.8) 8.7 (1.8) 0.417[mmol/mol] 73 (20) 72 (20) 72 (20)
ACR (mg/g) 118.1 (62.8) 58.8 (24.1) 110.7 (62.5) <0.001
BMI (kg/m2) 32.7 (6.8) 31.9 (6.8) 32.6 (6.8) <0.001
Diabetes duration (yrs) 4.5 (4.8) 4.0 (4.7) 4.4 (4.8) <0.001
Duration on insulin (yrs) 4.0 (6.4) 3.6 (6.1) 4.0 (6.4) 0.004
Weight (Kg) 91.7 (18.8) 91.0 (18.9) 91.6 (18.8) 0.131
Height (m) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 0.104
SBP (mmHg) 138.4 (23.3) 132.9 (22.8) 137.6 (23.3) <0.001
DBP (mmHg) 75.7 (10.9) 75.0 (10.6) 75.6 (10.9) 0.008
eGFR (mls/min/1.73m2) 59.0 (21.2) 65.6 (20.4) 59.9 (21.2) <0.001
TC (mmol/l) 4.6 (1.3) 4.6 (1.2) 4.6 (1.3) 0.715
HDL (mmol/l) 1.2 (0.4) 1.2 (0.4) 1.2 (0.4) 0.364
LDL (mmol/l) 2.4 (1.1) 2.4 (1.1) 2.4 (1.1) 0.574
Triglyceride (mmol/L) 2.2 (1.2) 2.0 (1.2) 2.1 (1.2) <0.001
Albumin (g/L) 4.0 (0.4) 4.1 (0.4) 4.0 (0.4) <0.001
Smoking status, No. (%)
Non-smoker 4633 (49) 740 (48) 5373 (49)
Ex-smoker 3551 (37) 568 (37) 4119 (37) 0.219
Current smoker 1338 (14) 244 (16) 1582 (14)
Alcohol status, No. (%)
Non-drinker 3194 (34) 487 (31) 3681 (33)
Ex-drinker 1091 (11) 180 (12) 1271 (11) 0.235
Current drinker 5237 (55) 885 (57) 6122 (55)
BMI Categories, No. (%)
Normal 1223 (13) 235 (15) 1458 (13)
Overweight 2231 (23) 399 (26) 2630 (24) 0.002
Obese 6068 (64) 918 (59) 6986 (63)
GLTs, No. (%)
Metformin 8163 (86) 1312 (85) 9475 (86) 0.216
Sulphonylurea 7316 (77) 1152 (74) 8468 (76) 0.025
Thiazolidinedione 3005 (32) 494 (32) 3499 (32) 0.831
GLP-1RA 1007 (11) 179 (12) 1186 (11) 0.258
SGLT2i 40 (0) 10 (1) 50 (0.5) 0.222
Glinides 428 (4) 72 (5) 500 (5) 0.800
DPP4i 1353 (14) 222 (14) 1575 (14) 0.921
Use of Medications, No. (%)
Aspirin 9213 (99) 1478 (99) 10691 (99) 0.138
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Antihypertensive 8493 (92) 1316 (89) 9809 (92) <0.001
- ACE inhibitors 7505 (81) 1154 (78) 8659 (81) 0.002
- ARBs 2957 (32) 409 (28) 3366 (31) 0.001
- Calcium channel blockers 5302 (56) 754 (51) 6056 (57) <0.001
- Beta-blockers 4807 (52) 699 (47) 5506 (51) <0.001
- Diuretics 9214 (96) 1479 (95) 10693 (94) 0.001
LLTs 8407 (91) 1347 (91) 9754 (91) 0.834
Comorbidities, No. (%) c
CHD 2992 (31) 404 (26) 3396 (31) <0.001
PAD 1365 (14) 185 (12) 1550 (14) 0.011
Heart Failure 1433 (15) 173 (11) 1606 (15) <0.001
Hypoglycaemia 1711 (18) 267 (17) 1978 (18) 0.465
Abbreviations:
GLP-1RA (Glucagon-like peptide-1 receptor agonist); SGLT2i (Sodium-glucose Cotransporter-2 (SGLT2)
Inhibitors); DPP4i (Dipeptidyl-peptidase 4 inhibitors); GLTs (Glucose Lowering Therapies); BMI (body mass
index); SBP (systolic blood pressure); DBP (diastolic blood pressure); HbA1c (hemoglobin A1c); HDL (high-
density lipoprotein); LDL (low-density lipoprotein); TC (total cholesterol); eGFR (estimated glomerular filtration
rate); LLTs (lipid lowering therapies); PAD (peripheral arterial disease); CHD (coronary heart disease); ACR
(albumin creatinine ratio); ACEi (Angiotensin Converting Enzyme Inhibitors); ARBs (Angiotensin II Receptor
Blockers); SD (standard deviation)
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Table 2: Comparison of number of events, Event rate and Hazard Ratio of the Primary
Outcomes between the treatment groups.
Primary End Points
Post One-year ACR
≥300mg/g 
(n = 9522)
<300mg
(n = 1552) p-value
All-Cause Mortality
Number of deaths 621 61
Death rates (95%CI) 16.7 (15.5 – 18.1) 9.7 (7.6 – 12.5)
HR (95%CI) 1 (reference) 0.57 (0.44 – 0.75) <0.001
aHRa (95%CI) 1 (reference) 0.69 (0.52 – 0.91) 0.008
Cardiovascular Eventsb
Number of events 438 50
Event rates (95%CI) 13.4 (12.2 – 14.7) 9.0 (6.8 – 11.8)
HR (95%CI) 1 (reference) 0.67 (0.50 – 0.90) 0.007
aHR (95%CI) 1 (reference) 0.73 (0.54 – 0.98) 0.041
Abbreviations: HR, hazard ratio; aHR, Adjusted Hazard Ration; ACR, albumin to creatinine ratio.
a Hazard ratio in both all-cause mortality and CV events was adjusted for age, BMI, duration of diabetes,
gender, Socio-economic status, change in HbA1c, Systolic and Diastolic BP, Change in Mean Arterial
Pressure (MAP), Lipid profile, Use of antihypertensive medications and comorbidities as Heart failure,
CHD and PAD.
bCardiovascular Events – Composite of non-fatal Myocardial Infarction and Stroke
Table 3: Comparison of number of events, Event rate and Hazard Ratio of the Secondary
Outcomes between the treatment groups.
Secondary End Points
Post One-year ACR
≥300mg/g 
(n = 9522)
<300mg/g
(n = 1552) p-value
Composite Outcomea
Number of events 1062 111
Event ratesb (95%CI) 32.5 (30.6 - 34.5) 19.9 (16.5 - 24.0)
HR (95%CI) 1 (reference) 0.61 (0.50 – 0.74) <0.001
aHRc (95%CI) 1 (reference) 0.73 (0.59 – 0.89) 0.002
Non-fatal Myocardial Infarction
Number of events 64 5
Event rates (95%CI) 1.8 (1.4 – 2.3) 0.8 (0.3 – 2.0)
HR (95%CI) 1 (reference) 0.46 (0.18 – 1.14) 0.094
aHR (95%CI) 1 (reference) 0.66 (0.26 – 1.70) 0.387
Non-fatal Stroke
Number of events 374 45
Event rates (95%CI) 11.1 (10.0 – 12.3) 7.9 (5.9 – 10.6)
HR (95%CI) 1 (reference) 0.71 (0.52 – 0.97) 0.030
aHR (95%CI) 1 (reference) 0.72 (0.52 – 0.97) 0.032
Abbreviations: HR, hazard ratio; aHR, Adjusted Hazard Ration; ACR, albumin to creatinine ratio.
aComposite Outcome – Composite of All-cause mortality, non-fatal Myocardial Infarction and Stroke
b Rates are expressed per 1000 person-years
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cHazard ratio in all the secondary endpoints was adjusted for age, BMI, duration of diabetes, gender,
Socio-economic status, change in HbA1c, Systolic and Diastolic BP, Change in Mean Arterial Pressure
(MAP), Lipid profile, Use of antihypertensive medications and comorbidities as Heart failure, CHD and
PAD.



